Lineage Cell Therapeutics, Inc. (LCTX) Shows Vision Gains in Phase 1/2a OpRegen Trial

In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Lineage Cell Therapeutics, Inc. is one of them.

Lineage Cell Therapeutics, Inc. (NYSE:LCTX) is a clinical-stage biotech company developing allogeneic “off-the-shelf” cell therapies for neurological and ophthalmic disorders. Its proprietary platform engineers human cells to replace or support dysfunctional cells caused by degenerative diseases, injuries, or aging.

In August 2025, the business reported positive 36-month Phase 1/2a results for RG6501 (OpRegen), a retinal pigment epithelial therapy for geographic atrophy, a form of age-related macular degeneration. Patients showed sustained vision improvements of +6.2 ETDRS letters, suggesting potential disease stabilization from a single administration. The data, presented at Clinical Trials at the Summit 2025, reinforces OpRegen’s promise as a therapy licensed to Genentech and Roche for further development, positioning Lineage among the best penny stocks in the biotech space.

Lineage Cell Therapeutics, Inc. (NYSE:LCTX) also treated its first chronic spinal cord injury patient in a new OPC1 trial, marking a milestone in expanding clinical applications beyond ophthalmology. Additionally, Lineage partnered with William Demant Invest A/S to co-develop ReSonance™, a cell transplant program targeting auditory nerve restoration for sensorineural hearing loss. The collaboration includes up to $12 million in funding over three years for preclinical development, cell manufacturing, and regulatory preparations.

Lineage Cell Therapeutics, Inc. (LCTX) Shows Vision Gains in Phase 1/2a OpRegen Trial

Financially, Lineage Cell Therapeutics, Inc. (NYSE:LCTX) remains strong, holding $42.3 million in cash as of June 30, 2025, supporting operations into early 2027. Q2 2025 revenues doubled year-over-year to $2.8 million, driven by partnerships and licensing, while the company continues to invest in R&D and manufacturing capabilities. CEO Brian M. Culley highlighted the corporation’s clinical and business progress at major September investor conferences, emphasizing confidence in the pipeline and upcoming scale-up initiatives.

While we acknowledge the risk and potential of LCTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LCTX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.